中国杭州，2023 年6月3日——百力司康生物医药（杭州）有限公司（“百力司康”），一家致力于研究和开发差异化抗体偶联药物（ADC）的临床阶段的生物医药公司，宣布将在2023 年6月2日至6日举行的美国临床肿瘤学会（2023 ASCO 年会）上公布BB-1701 的Ⅰ期研究数据。 在这次会议上，将以海报的形式展示BB-1701在局部晚期/转移性HER2表达实体瘤受试者中的剂量递增的首次人体Ⅰ期研究，包括安全性、耐受性、药代动力学和抗肿瘤活性数据。 2023年5月8日，百力司康与卫材株式会社（总部：东京，“卫材”）宣布就 BB-1701 达成临床试验合作，百力司康将与卫材合作推进BB-1701的开发，造福全世界的患者。 摘要标题：评估BB-1701在局部晚期/转移性HER2表达实体瘤受试者中的安全性、耐受性、药代动力学和抗肿瘤活性的开放、多剂量、剂量递增、队列扩展的首次人体Ⅰ期研究 摘要编号：3029 分会场标题：发展疗法 - 分子靶向药物和肿瘤生物学 展示时间：2023年6月3日（周六）8:00 AM-11:00 AM/北京时间2023年6月3日（周六）9:00 PM-12:00 PM 关于BB-1701 BB-1701是一款由百力司康开发的由抗HER2抗体和艾立布林结合的ADC创新药，旨在为局部晚期和转移性HER2阳性实体瘤患者提供更加安全有效的治疗方案, 具有应用于多种肿瘤适应症的市场前景。BB-1701具有独特的作用机制（MOA），包括有效的旁路杀伤效应以及免疫原性细胞死亡（ICD）活性，目前正在进行中美I/II期国际多中心临床试验。 1 关于百力司康生物医药（杭州）有限公司
百力司康生物医药（杭州）有限公司（“百力司康”）由医药界富有经验的海归博士于2017年在浙江省杭州市钱塘区共同创建，是一家专注于抗肿瘤生物创新药的研发和产业化的临床阶段的生物医药企业。百力司康拥有独特的自主知识产权技术平台、丰富的ADC产品管线，以及能够支持抗体和ADC生产并应用于临床开发和早期商业化的GMP自有产能。百力司康已被认定为中国国家高新技术企业。秉承着“集百家之力，司大众之康”的公司核心价值理念，通过与国内外同行密切合作，百力司康会继续聚焦创新药，解决未满足的临床需求。 有关百力司康的更多信息，请访问 https://www.blissbiopharma.com。 2 关于卫材 卫材的企业理念是“将患者利益和公众健康放在首位，为提升其福祉做出贡献。”基于这一理念（也称为我们的关心人类健康（hhc）理念），公司的目标是通过缓解对健康的焦虑和减少健康差距，有效地为实现健康社会做出贡献。凭借由研发场地、生产基地和营销子公司组成的全球网络，针对医疗需求高度未满足的疾病，公司努力创造和交付创新产品，特别关注神经病学和肿瘤学战略领域。 此外，我们与全球合作伙伴共同开展的各项活动表明，我们继续致力于消除被忽视的热带疾病，这是联合国可持续发展目标（SDG）的目标之一（3.3）。 有关卫材的更多信息，请访问www.Eisai.com（全球总部：卫材株式会社），并通过Twitter、LinkedIn和Facebook联系。 3 媒体问询 百力司康生物医药（杭州）有限公司 电话：+86-0571-86808367 邮箱：office@blissbiopharma.com BLISSBIO TO PRESENT DATA ON BB-1701 PHASE 1 STUDY AT 2023 ASCO ANNUAL MEETING Hangzhou, China, June 3, 2023 -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, (“BlissBio”) a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced today BB-1701 Phase 1 study data will be presented at the American Society of Clinical Oncology (2023 ASCO Annual Meeting), to be held from June 2 to 6, 2023. At this meeting, there will be a poster presentation on safety, tolerability, pharmacokinetics, and antitumor activity in a first-in-human dose escalation Phase I study of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. As announced on May 8, 2023, BlissBio and Eisai Co., Ltd (Headquarters: Tokyo, “Eisai”) entered into a clinical trial collaboration for BB-1701, and BlissBio works with Eisai to advance the development of BB-1701 for the benefit of patients worldwide. Abstract Title: A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. Abstract Number: 3029 Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology Session Date and Time: 8:00am-11:00am (CDT), June 3rd, 2023 About BB-1701 BB-1701 is an innovative ADC developed by BlissBio consisting of anti-HER2 antibody and eribulin. It is designed to provide a safer and more effective treatment regimen for patients with locally advanced/metastatic HER2-expressing solid tumors and expected to have multiple market prospects for application in various tumor indications. BB-1701 has unique mechanism of action (MOA) including potent bystander effect and immunogenic cell death (ICD) activity. BB-1701 is conducting Phase I/II international clinical trials both in China and US. 1 About Bliss Biopharmaceutical (Hangzhou) Co., Ltd Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (“BlissBio”), is a clinical-stage biotech company dedicated on discovery, development and commercialization of anti-tumor biotherapeutics, founded by pharmaceutical veterans in 2017 in Hangzhou, Zhejiang province. BlissBio has established a unique and patented technical platform, a rich ADC-focusing pipeline, and GMP manufacture capability that could support antibody and ADC production for both clinical development and early commercialization. BlissBio has been nominated as a national high-tech biopharmaceutical enterprise in China. With “Together, We Improve Human Health” as the core value, through international and domestic collaborations, BlissBio will continue to focus on innovative drugs to address unmet medical needs. For more information please visit https://www.blissbiopharma.com 2 About Eisai Co., Ltd Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as our human health care (hhc) Concept), the company aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, the company’s continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on Twitter, LinkedIn and Facebook. 3 Media Inquiries Bliss Biopharmaceutical (Hangzhou) Co., Ltd TEL: +86-0571-86808367 E-mail: office@blissbiopharma.com
声明：本文观点仅代表作者本人，不代表煜森资本立场，欢迎在留言区交流补充。如需转载，请注明文章作者和来源。如涉及作品内容、版权和其它问题，请在本平台留言。
